The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letters to the EditorFull Access

Understanding Pregnancy’s Protective Effect on Drug Use Within a Developmental Framework

To the Editor: In the article by Kendler et al. (1), published in the October 2017 issue of the Journal, the authors analyzed Sweden’s national health registry data on nearly 150,000 women to examine pregnancy status in relation to drug use patterns, accounting for demographic, heritable, partner-related, and unmeasured individual-level confounding effects. Viewed as a natural intervention, the impact of pregnancy on drug use rivaled the effects of financial incentive–based (contingency management) interventions. Strikingly, this impact was equal, if not greater, in women with higher baseline risk factors for prenatal drug use (as shown in Table 2 in the article). The authors describe the mothers’ intrinsic motivation to protect their developing children by suspending drug use as evidence for the limitations of an exclusively brain-based view of drug abuse.

We present an expanded interpretation of the findings—one that incorporates brain-based models of addiction. Health-related behaviors of pregnant women can also be understood developmentally within a caregiving framework (2, 3). Maternal motivation to protect the fetus against drug exposure could be facilitated by highly evolutionarily conserved processes first described in mammalian species and increasingly characterized in human parental and nonparental contexts (4). These neurobiological models could be highly relevant for understanding why pregnancy confers a protective effect.

The study by Kendler and colleagues also has broader implications beyond the perinatal context. The ways that drug use and associated neuroadaptations may interrupt social and interpersonal processes have received significant attention (5). The findings from this study, together with prospective investigations that employ biomarker-verified reports of cessation during pregnancy (6, 7), now provide compelling evidence that social processes related to maternal caregiving can also interrupt addictive processes. In this way, the protective effect of pregnancy on drug use convincingly demonstrated in this study is a unique paradigm of how social and interpersonal processes can positively and powerfully influence addictive behaviors. This is encouraging because more effective and durable solutions to the treatment of substance use disorders are sorely needed.

From the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago.
Address correspondence to Dr. Massey ().

Supported by NIDA grant K23 DA037913 to Dr. Massey.

The content of this letter is solely the responsibility of the authors and does not necessarily represent the official views of NIDA or NIH.

The Department of Psychiatry and Behavioral Sciences at Northwestern University received contractual fees for Dr. Wisner’s consultation to Quinn Emanuel Urquhart & Sullivan, LLP (New York City), which represents Pfizer. Dr. Massey reports no financial relationships with commercial interests.

References

1 Kendler KS, Ohlsson H, Svikis DS, et al.: The protective effect of pregnancy on risk for drug abuse: a population, co-relative, co-spouse, and within-individual analysis. Am J Psychiatry 2017; 174:954–962LinkGoogle Scholar

2 Massey SH, Decety J, Wisner KL, et al.: Specification of change mechanisms in pregnant smokers for malleable target identification: a novel approach to a tenacious public health problem. Front Public Health 2017; 5:239Crossref, MedlineGoogle Scholar

3 Feldman R: The neurobiology of mammalian parenting and the biosocial context of human caregiving. Horm Behav 2016; 77:3–17Crossref, MedlineGoogle Scholar

4 Massey SH, Neiderhiser JM, Shaw DS, et al.: Maternal self concept as a provider and cessation of substance use during pregnancy. Addict Behav 2012; 37:956–961Crossref, MedlineGoogle Scholar

5 Volkow ND, Baler RD, Goldstein RZ: Addiction: pulling at the neural threads of social behaviors. Neuron 2011; 69:599–602Crossref, MedlineGoogle Scholar

6 Massey SH, Estabrook R, O’Brien TC, et al.: Preliminary evidence for the interaction of the oxytocin receptor gene (OXTR) and face processing in differentiating prenatal smoking patterns. Neurosci Lett 2015; 584:259–264Crossref, MedlineGoogle Scholar

7 Massey SH, Bublitz MH, Magee SR, et al.: Maternal-fetal attachment differentiates patterns of prenatal smoking and exposure. Addict Behav 2015; 45:51–56Crossref, MedlineGoogle Scholar